Clinical Trials Logo

Clinical Trial Summary

rabies mab CBB 1 is mainly used for passive immunization of patients bitten or scratched by rabies or other animals carrying rabies virus, this study mainly studies the safety, tolerability, pharmacokinetics, neutralizing antibody activity and immunogenic characteristics of rabies mAb CBB 1 in healthy adults


Clinical Trial Description

1. Evaluate and compare the safety, tolerability, pharmacokinetics, neutralizing antibody activity and immunogenicity of rabies virus after single doses of rabies mAb CBB 1 or rabies human immunoglobulin (HRIG) in healthy adults. 2. Evaluate and compare the safety, tolerability, pharmacokinetics, neutralizing antibody activity and immunogenicity characteristics of rabies virus after different doses of rabies mAb CBB 1 combination vaccine or HRIG combination vaccine in healthy adults. 3. Comparison of different doses of rabies mAb CBB 1 alone, different doses of rabies mAb CBB 1, combination vaccine or HRIG combination vaccine used in healthy adults after safety, tolerability, pharmacokinetics, rabies virus neutralization antibody activity and immunogenicity characteristics, further evaluation of drug interaction, for subsequent clinical trials to explore the optimal dose. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05832073
Study type Interventional
Source Changchun BCHT Biotechnology Co.
Contact
Status Not yet recruiting
Phase Early Phase 1
Start date April 30, 2023
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05382650 - Survey of Human Rabies Immune Globulin Safety in Children
Completed NCT04213950 - Improving Adherence to Rabies PEP Guideline Recommendations N/A